000			03997nam a2200433 i 4500
999			_c362877 _d362877 _x1
001			362877
003			ES-MaUEC
005			20230102121628.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			210602s2021 sz | o |||| 0|eng d
020			_a9783030719135
024	7		_a10.1007/978-3-030-71913-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC643 _b2021 EB
245	0	0	_aChronic Myeloid Leukemia _cedited by Rüdiger Hehlmann
250			_aSecond edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (IX, 273 páginas) _b42 ilustraciones, 35 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aHematologic Malignancies _x2197-9774
505	0		_aCytogenetics of Chronic Myeloid Leukemia (CML) -- The Biology and Pathogenesis of Chronic Myeloid Leukaemia -- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy -- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors -- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia -- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia -- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update -- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death -- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- The Role of Hematopoietic Stem Cell Transplantation in CML -- CML end-phase and blast crisis: implications and management -- The Interferon-alpha Revival in CML -- Managing Pregnancy in Chronic Myeloid Leukemia -- Response-Related Predictors of Survival and of Treatment Free Remission in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response. .
520			_aThis book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. .
988			_aSpringer_Medicine_2021
650		7	_2embne _9140673 _aLeucemia
700	1		_aHehlmann, Rüdiger _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030719128
776	0	8	_iPrinted edition: _z9783030719142
776	0	8	_iPrinted edition: _z9783030719159
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-71913-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2022 _dz _eb _zSI